Back to top
more

Amphastar Pharmaceuticals (AMPH)

(Delayed Data from NSDQ)

$42.02 USD

42.02
342,556

+0.91 (2.21%)

Updated Apr 29, 2024 04:00 PM ET

After-Market: $42.06 +0.04 (0.10%) 7:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (95 out of 252)

Industry: Medical - Generic Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Will Global Industrial Unit Aid Ecolab (ECL) in Q4 Earnings?

by Zacks Equity Research

Ecolab's (ECL) strong segmental sales and acquisition-driven strategies are likely to drive fourth-quarter results.

    Henry Schein (HSIC) Q4 Earnings to Show Growth in All Lines?

    by Zacks Equity Research

    Henry Schein (HSIC) likely to gain on strength across all business segments in Q4.

      AmerisourceBergen (ABC) Gains on World Courier Unit Strength

      by Zacks Equity Research

      AmerisourceBergen's (ABC) World Courier business gets GDP designation.

        Can Pharmacy Services Drive CVS Health's (CVS) Q4 Earnings?

        by Zacks Equity Research

        CVS Health's (CVS) Q4 earnings are expected to gain from strength in the Pharmacy Services segment.

          What's in Store for Cardinal Health (CAH) in Q2 Earnings?

          by Zacks Equity Research

          Pricing pressure in generics portfolio is likely to mar Cardinal Health's (CAH) top line in Q2.

            Can Molecular Diagnostics Arm Up Hologic (HOLX) Q1 Earnings?

            by Zacks Equity Research

            Molecular Diagnostics unit's stellar performance in the first quarter of 2018 is likely to drive Hologic (HOLX) in Q1.

              Will Higher System Sales Drive Cerner's (CERN) Q4 Earnings?

              by Zacks Equity Research

              Cerner (CERN) expects solid Q4 revenues on a surge in bookings. Stiff competition remains a concern.

                Amphastar (AMPH) in Focus: Stock Moves 9.7% Higher

                by Zacks Equity Research

                Amphastar Pharmaceuticals (AMPH) was a big mover last session, as the company saw its shares rise almost 10% on the day.

                  Arpita Dutt headshot

                  Pharma Stock Roundup: Cempra Plunges to 52-Week Low, Shire Drug Label Expanded

                  by Arpita Dutt

                  Key highlights this week include complete response letters from the FDA for a couple of companies with Cempra (CEMP) plunging to a 52-week low.

                    Amphastar Stock Down on CRL for Asthma Drug in the U.S.

                    by Zacks Equity Research

                    Amphastar Pharmaceuticals, Inc. (AMPH) announced that its subsidiary, Armstrong Pharmaceuticals, Inc., has received a Complete Response Letter (CRL) from the FDA for Primatene Mist (epinephrine inhalation aerosol).